Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two

Core Insights - Hemostemix Inc. has initiated its strategy to acquire cardiology practices, starting with two prominent cardiologists in the Dominican Republic, Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, for 2,000,000 shares each [1][11] - The long-term strategy aims to integrate profitable medical practices to enhance the commercialization of ACP-01 treatments, creating a sustainable patient flow for the company [2][6] - The two cardiologists have extensive experience, having treated over 200 patients with ACP-01, positioning them as key figures in the company's expansion efforts [3][7] Company Strategy - The acquisition of these practices is part of a broader plan to establish a clinical and commercial presence internationally, with a focus on patient treatment flow and increasing practitioner engagement [2][6] - Hemostemix aims to replicate its business model across various markets, including Florida, Puerto Rico, and Canada, leveraging the expertise of the acquired cardiologists [6][7] Clinical Expertise - Dr. Fernandez-de-Castro and Dr. Figueroa will contribute their expertise in treating various cardiovascular conditions, including Angina, Ischemic and Dilated Cardiomyopathy, Congestive Heart Failure, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia, and Vascular Dementia [5][4] - Their established reputations and patient bases in the Dominican Republic are expected to facilitate the implementation of ACP-01 therapy [4][5] Financial Aspects - The TSXV has approved an extension for a non-brokered private placement, allowing Hemostemix to raise funds at $0.11 per unit, with total gross proceeds of $461,230 raised to date [8] - Each unit consists of one common share and one warrant, with the potential for additional shares to be acquired at $0.15 per share [8] Company Background - Hemostemix is an autologous stem cell therapy platform company, recognized for its development of VesCell™ (ACP-01), which has shown promising results in clinical studies for various cardiovascular diseases [9] - The company has completed seven clinical studies involving 318 subjects, demonstrating the safety and efficacy of ACP-01 [9]